Case Details
- Citation: [2021] SGCA 25
- Title: Crest Capital Asia Pte Ltd and others v OUE Lippo Healthcare Ltd (formerly known as International Healthway Corporation Ltd) and another and other appeals
- Court: Court of Appeal of the Republic of Singapore
- Date of Decision: 30 March 2021
- Coram: Judith Prakash JCA; Steven Chong JCA; Belinda Ang Saw Ean JAD
- Case Numbers: Civil Appeal Nos 113, 132 and 135 of 2020
- Judgment Type: Appeals from the High Court decision in [2020] SGHC 142
- Plaintiff/Applicant (Respondents in CA): OUE Lippo Healthcare Ltd (formerly known as International Healthway Corporation Ltd) and another
- Defendant/Respondent (Appellants in CA): Crest Capital Asia Pte Ltd and others
- Parties (key entities): Crest Capital Asia Pte Ltd; Crest Catalyst Equity Pte Ltd; The Enterprise Fund III Ltd; VMF3 Ltd; Value Monetization III Ltd; OUE Lippo Healthcare Ltd; IHC Medical Re Pte Ltd; Lim Beng Choo; Fan Kow Hin; Aathar Ah Kong Andrew (7th defendant below, not an appellant)
- Legal Areas: Tort — Conspiracy; Agency — Evidence of agency; Agency — Principal; Trusts — Accessory liability; Damages — Assessment
- Statutes Referenced: Companies Act (Cap 50, 2006 Rev Ed), including s 76A(1A)(a)(i); and “A of the Companies Act” (as reflected in the metadata)
- Cases Cited: [2020] SGHC 142; [2021] SGCA 25 (this decision)
- Judgment Length: 38 pages, 21,939 words
- Counsel (high level): Tan Chee Meng SC and others (for first to third appellants in CA 113/2020); Toby Landau QC and others (for fourth and fifth appellants in CA 113/2020); Goh Kok Leong and others (for appellant in CA 132/2020); Lok Vi Ming SC and others (for appellant in CA 135/2020); Lee Eng Beng SC and others (for respondents in CAs 113, 132 and 135/2020)
Summary
This Court of Appeal decision arose from a complex dispute over financing arrangements connected to the acquisition of shares in IHC (International Healthway Corporation Ltd, later known as OUE Lippo Healthcare Ltd). The litigation followed an earlier Court of Appeal ruling in The Enterprise Fund III Ltd and others v OUE Lippo Healthcare Ltd (formerly known as International Healthway Corp Ltd) [2019] 2 SLR 524 (“The Enterprise Fund III”), in which the Court held that a transaction structure involving a standby credit facility, open market share acquisitions, and a trust arrangement was void under s 76A(1A)(a)(i) of the Companies Act. However, the Court also held that the open market acquisitions were “saved” because they involved dispositions of book-entry securities, with important consequences for who became the legal and beneficial owner of the shares.
After that earlier decision, IHC and its related entities sued various parties involved in providing the standby facility and related transactions, alleging tortious liability beyond contractual exposure. Following a trial, the High Court found multiple defendants jointly and severally liable for the respondents’ losses. The present appeals required the Court of Appeal to revisit how tort principles—especially conspiracy and accessory liability—operate in a setting where corporate actors act through agents and where multiple defendants are sued on different tortious theories.
The Court of Appeal emphasised that authorisation to contract does not automatically translate into tortious attribution. It required a separate, principal-specific factual inquiry into whether the acts or omissions of representatives/agents could be attributed to each principal, and whether the requisite knowledge and complicity were present. The Court also addressed how different tort claims against different defendants may (or may not) support joint and several liability, depending on the legal basis and the evidence.
What Were the Facts of This Case?
The respondents, IHC and IHC Medical Re Pte Ltd, were part of a group with further ownership interests including IHC Healthcare REIT and two Australian trusts (IHC Australia First Trust and IHC Australia Second Trust) which owned properties in Australia. The dispute, however, centred on financing arrangements that were designed to support IHC’s share-related activities and to manage perceived market risks.
The appellants in CA 113/2020 were collectively referred to as the “Crest Entities”: Crest Capital Asia Pte Ltd (a fund administration company and holding company), Crest Catalyst Equity Pte Ltd (a fund management company), and three funds administered/managed by Crest Capital and Crest Catalyst—The Enterprise Fund III Ltd (“EFIII”), VMF3 Ltd (“VMF3”), and Value Monetization III Ltd (“VMIII”). In CA 132/2020, the appellant was Ms Lim, who held senior roles within IHC over different periods. In CA 135/2020, the appellant was Mr Fan, a co-founder of IHC with substantial shareholding and executive roles during the relevant time.
Two credit facilities were central. The first was the “Standby Facility”, a short-term credit facility of up to $20m executed on 30 July 2015 for “general working capital”. The lenders were EFIII, VMF3 and VMIII (together, the “Standby Investors”). The facility provided fixed interest (“standby fees”) of 3.5% per month on the full $20m for a minimum of five months, with maturity on 30 December 2015. The second was the “Geelong Facility”, a loan of $11.5m executed on 17 June 2015, with IHC Medical Re as borrower and EFIII and VMF3 as lenders.
Security arrangements included personal guarantees from Mr Fan and Mr Aathar (a co-founder of IHC who was a substantial shareholder but not formally part of management), and share charges granted by IHC over shares in IHC Medical Re and other subsidiaries. These were implemented through deeds of share charges dated June and July 2015.
The genesis of the Standby Facility began with discussions among key individuals, including Mr Fan, Mr Aathar, and Mr Tan (an investment director of Crest Capital). On 3 April 2015, they met to discuss the need for a standby line. On the morning of 4 April 2015, Mr Aathar emailed Mr Tan (copied to Mr Fan) describing an “unusual sale pattern” and a “shortist” holding large volumes of IHC shares, suggesting an imminent shorting activity. The email proposed that Crest provide a $20m standby line, with interest at 3.5% per month, and stated that time was of the essence, with a small amount available immediately for standby use.
Later that afternoon, Mr Aathar sent another email stating that he could give a firm undertaking from IHC that security arrangements would be restored and reinstated to Crest’s satisfaction. Subsequent correspondence on 9 April 2015 involved additional individuals, including Ms Lim and IHC’s CEO at the time, Mr Chia Kwok Ping, as well as Mr CP Lim, an investment analyst with Crest Capital. A term sheet circulated among these individuals contemplated securing the facility through guarantees from Mr Aathar and Mr Fan and a pledge of IHC shares purchased through a “Fund” (a term not defined in the term sheet). The term sheet was signed by Mr Chia as CEO of IHC and by Mr Aathar and Mr Fan as guarantors, and then transmitted to Mr Tan.
Although the excerpt provided is truncated, the Court of Appeal’s introduction makes clear that the earlier Court of Appeal decision in The Enterprise Fund III had already determined that the overall transaction structure was void under the Companies Act, while preserving the validity of the open market acquisitions due to the statutory “book-entry securities” saving provision. The present appeals therefore did not revisit the statutory voidness directly; instead, they focused on whether tortious liability could be established against the appellants for losses allegedly suffered beyond the contractual liability under the standby facility.
What Were the Key Legal Issues?
The Court of Appeal identified several issues that are particularly instructive for tort and agency analysis in corporate financing disputes. First, the Court had to consider when and whether a principal can be held tortiously liable for the acts or omissions of its representatives or agents. The Court stressed that authorisation to enter into contracts with third parties does not inexorably lead to tortious attribution. Instead, the inquiry must be separate and fact-specific, and it must be conducted with respect to each principal individually.
Second, the Court had to address the evidential and doctrinal requirements for establishing torts such as conspiracy and accessory liability. In conspiracy, the focus is on agreement and the requisite mental element; in accessory liability (including trust-related accessory liability), the focus is on knowledge and participation in wrongdoing. The Court’s approach required careful attention to what each defendant knew and how each was implicated.
Third, the Court addressed a procedural and substantive question about joint and several liability. Where different defendants are sued on different tortious claims, the Court had to consider whether joint and several liability could properly arise, and if so, under what circumstances. This required the Court to reconcile the different causes of action with the evidence and the legal basis for attributing responsibility.
How Did the Court Analyse the Issues?
The Court of Appeal began by framing the central analytical caution: corporate entities act through representatives and agents, but tort attribution is not automatic. The Court observed that it is tempting to assume that because an agent is authorised to contract, the principal must also be liable in tort for the agent’s conduct. The Court rejected that shortcut. Instead, it required a separate factual inquiry into whether the acts or omissions could be attributed to each principal, and whether the principal’s knowledge and complicity were established on the evidence.
This principal-specific approach matters because different principals may be represented by the same lawyers and may participate in the same transaction. Yet, the Court warned that the “critical distinction” between principals’ knowledge and complicity might not be adequately fleshed out if the analysis is too generic. The Court’s reasoning therefore reflects a disciplined evidential methodology: the court must identify the relevant conduct, determine the mental element for the tort in question, and then assess whether the principal can be said to have the requisite involvement.
In addressing conspiracy and accessory liability, the Court’s analysis (as signposted in the introduction) would necessarily involve scrutinising the communications and the transaction structure. The Morning Email and Afternoon Email, and the subsequent term sheet correspondence, were not merely background facts; they were potential evidence of knowledge, purpose, and the intended use of the facility. The Court’s approach to such evidence would likely focus on whether the communications demonstrated an understanding of the market activity being addressed, and whether the parties’ roles aligned with the alleged wrongdoing.
Further, the Court’s reasoning had to operate in the shadow of The Enterprise Fund III. That earlier decision had already declared the transaction void under the Companies Act, but it had also preserved the validity of the open market acquisitions due to the statutory saving provision. This created a nuanced legal landscape: even if contractual liability under the standby facility did not attach in the same way, tortious liability might still be argued if the defendants’ conduct met the elements of the torts pleaded. The Court therefore had to ensure that the respondents’ tort claims were not simply repackaged contractual arguments, and that they were supported by the distinct requirements of conspiracy and accessory liability.
Finally, on joint and several liability, the Court’s analysis would have required careful legal mapping between each cause of action and each defendant. Joint and several liability is not a default consequence of multiple defendants being involved in the same overall transaction. Rather, it depends on whether the legal basis for holding each defendant liable is established and whether the tortious conduct is sufficiently connected to justify the allocation of responsibility. The Court’s emphasis on separate factual inquiry for each principal reinforces this: even if one defendant’s conduct is proven, that does not automatically establish the same level of responsibility for another defendant on a different tort theory.
What Was the Outcome?
The Court of Appeal’s decision disposed of the appeals arising from the High Court’s finding of joint and several liability. While the provided extract does not include the operative orders, the structure of the Court of Appeal’s reasoning indicates that the Court scrutinised the High Court’s attribution and evidential findings, particularly the extent to which agency and authorisation were treated as sufficient bases for tortious liability.
Practically, the outcome would have clarified the evidential thresholds for establishing tortious liability in corporate financing contexts, and it would have guided how courts should approach principal-specific knowledge and complicity, as well as the circumstances in which joint and several liability can be imposed across multiple tort claims and multiple defendants.
Why Does This Case Matter?
This case is significant for practitioners because it provides a structured approach to tort attribution in corporate settings. The Court of Appeal’s insistence on a separate, principal-specific factual inquiry is a reminder that agency principles in contract do not automatically determine tort outcomes. For law firms litigating complex commercial disputes, this decision underscores the need to plead and prove the mental element and the factual involvement of each defendant principal, rather than relying on broad transaction-level narratives.
Second, the decision is important for conspiracy and accessory liability analysis. Where wrongdoing is alleged in connection with financing structures, courts will examine communications, transaction mechanics, and the parties’ understanding of the purpose and risks. The decision therefore supports a more evidence-driven approach: contemporaneous emails, term sheets, and correspondence can become central to proving knowledge and complicity, but they must be tied to the legal elements of each tort.
Third, the Court’s discussion of joint and several liability across different tort claims has practical implications for both plaintiffs and defendants. Plaintiffs must ensure that each defendant’s liability is grounded in the correct legal basis and supported by evidence, while defendants can challenge overbroad findings that treat multiple defendants as interchangeable. For damages assessment, the case also highlights the importance of ensuring that liability theories align with the losses claimed and the legal causation framework.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), including s 76A(1A)(a)(i) (voidness of certain transactions) and the statutory saving relating to dispositions of book-entry securities (as applied in The Enterprise Fund III)
- “A of the Companies Act” (as reflected in the case metadata)
Cases Cited
- The Enterprise Fund III Ltd and others v OUE Lippo Healthcare Ltd (formerly known as International Healthway Corp Ltd) [2019] 2 SLR 524
- Crest Capital Asia Pte Ltd and others v OUE Lippo Healthcare Ltd (formerly known as International Healthway Corporation Ltd) and another and other appeals [2021] SGCA 25
- [2020] SGHC 142
Source Documents
This article analyses [2021] SGCA 25 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.